Update on genetic and molecular markers associated with myelodysplastic syndromes

References

• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–199
   PubMed Web of Science ®Google Scholar
• Brunning R D, Bennett J M, Flandrin G, Matutes E, Head D, Vardiman J W, . Myelodysplastic syndromes. World Health Organization Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues, E S Jaffe, N L Harris, H Stein, J W Vardiman, et al. IARC Press, Lyon 2001; 1: 62–73
   Google Scholar
• Fenaux P. Chromosome and molecular abnormalities in myelodysplastic syndromes. Int J Hematol 2001; 73: 429–437
   PubMed Web of Science ®Google Scholar
• Hofmann W K, Koeffler H P. Myelodysplastic syndrome. Annu Rev Med 2005; 56: 1–16
   PubMed Web of Science ®Google Scholar
• Valent P, Horny H P, Bennett J M, Fonatsch C, Germing U, Greenberg P, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res 2007; 31: 727–736
   PubMed Web of Science ®Google Scholar
• Nimer S D. Myelodysplastic syndromes. Blood 2008; 111: 4841–4851
   PubMed Web of Science ®Google Scholar
• Aul C, Gattermann N, Heyll A, Gerrming U, Derigs G, Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992; 6: 52–59
   PubMed Web of Science ®Google Scholar
• Mufti G J, Stevens J R, Oscier D G, Hamblin T J, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985; 59: 425–433
   PubMed Web of Science ®Google Scholar
• Toyama K, Ohyashiki K, Yoshida Y, Abe T, Asano S, Hirai H, et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia 1993; 7: 499–508
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau M M, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088
   PubMed Web of Science ®Google Scholar
• Malcovati L, Germing U, Kuendgen A, Della Porta M G, Pascutto C, Invernizzi R. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503–3510
   PubMed Web of Science ®Google Scholar
• Mhawech P, Saleem A. Myelodysplastic syndrome: review of the cytogenetic and molecular data. Crit Rev Oncol Hematol 2001; 40: 229–238
   PubMed Web of Science ®Google Scholar
• Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007; 110: 4385–4395
   PubMed Web of Science ®Google Scholar
• Schanz J, Slovak M L, Ohyashiki K, Solé F, del Mar Mallo M, Steidl C, et al. New prognostic data on rare cytogenetic abnormalities in MDS: a collaborative study of the international working group on MDS cytogenetics. Blood 2008; 112: 2688
   Google Scholar
• Giagounidis A A, Germing U, Aul C. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res 2006; 12: 5–10
   PubMed Web of Science ®Google Scholar
• List A, Dewald G, Bennett J M, Giagounidis A A, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456–1465
   PubMed Web of Science ®Google Scholar
• Cutler C S, Lee S J, Greenberg P, Deeg H J, Pérez W S, Anasetti C, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104: 579–585
   PubMed Web of Science ®Google Scholar
• de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N, et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary leukemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000; 110: 620–630
   PubMed Web of Science ®Google Scholar
• Jaju R J, Boultwood J, Oliver F J, Kostrzewa M, Fidler C, Parker N, et al. Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome. Genes Chromosomes Cancer 1998; 22: 251–256
   PubMed Web of Science ®Google Scholar
• Wlodarska I, Selleri L, La Starza R, Paternotte C, Evans G A, Boogaerts M, et al. Molecular cytogenetics localizes two new breakpoints on 11q23.3 and 21q11.2 in myelodysplastic syndrome with t(11;21) translocation. Genes Chromosomes Cancer 1999; 24: 199–206
   PubMed Web of Science ®Google Scholar
• Döhner K, Brown J, Hehmann U, Hetzel C, Stewart J, Lowther G, et al. Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders. Blood 1998; 92: 4031–4035
   PubMed Web of Science ®Google Scholar
• Bench A J, Nacheva E P, Hood T L, Holden J L, French L, Swanton S, et al. Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG). Oncogene 2000; 19: 3902–3913
   PubMed Web of Science ®Google Scholar
• Mitani K, Ogawa S, Tanaka T, Miyoshi H, Kurokawa M, Mano H, et al. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J 1994; 13: 504–510
   PubMed Web of Science ®Google Scholar
• Nucifora G, Begy C R, Kobayashi H, Roulston D, Claxton D, Pedersen-Bjergaard J, et al. Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations. Proc Natl Acad Sci USA 1994; 91: 4004–4008
   PubMed Web of Science ®Google Scholar
• Morishita K, Parganas E, William C L, Whittaker M H, Drabkin H, Oval J, et al. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300–400 kilobases on chromosome band 3q26. Proc Natl Acad Sci USA 1992; 89: 3937–3941
   PubMed Web of Science ®Google Scholar
• Suzukawa K, Parganas E, Gajjar A, Abe T, Takahashi S, Tani K, et al. Identification of a breakpoint cluster region 3′ of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26). Blood 1994; 84: 2681–2688
   PubMed Web of Science ®Google Scholar
• Vinatzer U, Mannhalter C, Mitterbauer M, Gruener H, Greinix H, Schmidt H H, et al. Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia. Genes Chromosomes Cancer 2003; 36: 80–89
   PubMedGoogle Scholar
• Soderholm J, Kobayashi H, Mathieu C, Rowley J D, Nucifora G. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator. Leukemia 1997; 11: 352–358
   PubMed Web of Science ®Google Scholar
• Aytekin M, Vinatzer U, Musteanu M, Raynaud S, Wieser R. Regulation of the expression of the oncogene EVI1 through the use of alternative mRNA 5′-ends. Gene 2005; 356: 160–168
   PubMed Web of Science ®Google Scholar
• Wieser R. The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. Gene 2007; 396: 346–357
   PubMed Web of Science ®Google Scholar
• Mitani K. Molecular mechanisms of leukemogenesis by AML1/EVI-1. Oncogene 2004; 23: 4263–4269
   PubMed Web of Science ®Google Scholar
• Nanjundan M, Nakayama Y, Cheng K W, Lahad J, Liu J, Lu K, et al. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res 2007; 67: 3074–3084
   PubMed Web of Science ®Google Scholar
• Buonamici S, Li D, Chi Y, Zhao R, Wang X, Brace L, et al. EVI1 induces myelodysplastic syndrome in mice. J Clin Invest 2004; 114: 713–719
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The medical research council adult and children's leukaemia working parties. Blood 1998; 92: 2322–2333
   PubMed Web of Science ®Google Scholar
• Yin C C, Cortes J, Barkoh B, Hayes K, Kantarjian H, Jones D. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy. Cancer 2006; 106: 1730–1738
   PubMed Web of Science ®Google Scholar
• Reiter E, Greinix H, Rabitsch W, Keil F, Schwarzinger I, Jaeger U, et al. Low curative potential of bone marrow transplantation for highly aggressive acute myelogenous leukemia with inversioin inv (3)(q21q26) or homologous translocation t(3;3) (q21;q26). Ann Hematol 2000; 79: 374–377
   PubMed Web of Science ®Google Scholar
• Weisser M, Haferlach C, Haferlach T, Schnittger S. Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3)(q21;q26) positive AML. Leuk Lymphoma 2007; 48: 2145–2151
   PubMed Web of Science ®Google Scholar
• Sperr W, Valent P. Biology and clinical features of myeloid neoplasms with inv(3)(q21q26) or t(3;3)(q21q26). Leuk Lymphoma 2007; 48: 2096–2097
   PubMed Web of Science ®Google Scholar
• Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol 2008; 87: 515–526
   PubMed Web of Science ®Google Scholar
• Wlodarska I, Mecucci C, Marynen P, Guo C, Franckx D, La Starza R, et al. TEL gene is involved in myelodysplastic syndromes with either the typical t(5;12)(q33;p13) translocation or its variant t(10;12)(q24;p13). Blood 1995; 85: 2848–2852
   PubMed Web of Science ®Google Scholar
• Carroll M, Tomasson M H, Barker G F, Golub T R, Gilliland D G. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci USA 1996; 93: 14845–14850
   PubMed Web of Science ®Google Scholar
• Steer E J, Cross N C. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta. Acta Haematol 2002; 107: 113–122
   PubMed Web of Science ®Google Scholar
• Apperley J F, Gardembas M, Melo J V, Russell-Jones R, Bain B J, Baxter E J, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347: 481–487
   PubMed Web of Science ®Google Scholar
• Boultwood J, Fidler C, Strickson A J, Watkins F, Gama S, Kearney L, et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood 2002; 99: 4638–4641
   PubMed Web of Science ®Google Scholar
• Ebert B L, Pretz J, Bosco J, Chang C Y, Tamayo P, Galili N, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008; 451: 335–339
   PubMed Web of Science ®Google Scholar
• Pellagatti A, Jädersten M, Forsblom A M, Cattan H, Christensson B, Emanuelsson E K, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA 2007; 104: 11406–11411
   PubMed Web of Science ®Google Scholar
• Hirai H, Kobayashi Y, Mano H, Hagiwara K, Maru Y, Omine M, et al. A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. Nature 1987; 327: 430–432
   PubMed Web of Science ®Google Scholar
• Liu E, Hjelle B, Morgan R, Hecht F, Bishop J M. Mutations of the Kirsten-ras proto-oncogene in human preleukaemia. Nature 1987; 330: 186–188
   PubMed Web of Science ®Google Scholar
• Harada H, Harada Y, Niimi H, Kyo T, Kimura A, Inaba T. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 2004; 103: 2316–2324
   PubMed Web of Science ®Google Scholar
• Nolte F, Hofmann W K. Myelodysplastic syndromes: molecular pathogenesis and genomic changes. Ann Hematol 2008; 87: 777–795
   PubMed Web of Science ®Google Scholar
• Watanabe-Okochi N, Kitaura J, Ono R, Harada H, Harada Y, Komeno Y, et al. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood 2008; 111: 4297–4308
   PubMed Web of Science ®Google Scholar
• Niimi H, Harada H, Harada Y, Ding Y, Imagawa J, Inaba T, et al. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations. Leukemia 2006; 20: 635–644
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Albitar M, Cortes J E, Estey E H, Faderl S H, Garcia-Manero G, et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 2004; 22: 1287–1292
   PubMed Web of Science ®Google Scholar
• Gore S D. Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies. Nat Clin Pract Oncol 2005; 2(Suppl. 1)S30–S35
   PubMedGoogle Scholar
• Steensma D P, Dewald G W, Lasho T L, Powell H L, McClure R F, Levine R L, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both ‘atypical’ myeloproliferative disorders and myelodysplastic syndromes. Blood 2005; 106: 1207–1209
   PubMed Web of Science ®Google Scholar
• Ohyashiki K, Aota Y, Akahane D, Gotoh A, Miyazawa K, Kimura Y, et al. The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients. Leukemia 2005; 19: 2359–2360
   PubMed Web of Science ®Google Scholar
• Ingram W, Lea N C, Cervera J, Germing U, Fenaux P, Cassinat B, et al. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia 2006; 20: 1319–1321
   PubMed Web of Science ®Google Scholar
• Gattermann N, Billiet J, Kronenwett R, Zipperer E, Germing U, Nollet F, et al. High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count > 600 × 109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable. Blood 2007; 109: 1334–1335
   PubMed Web of Science ®Google Scholar
• Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi E D, Theil K S, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 2006; 108: 2173–2181
   PubMed Web of Science ®Google Scholar
• Fritsche-Polanz R, Jordan J H, Feix A, Sperr W R, Sunder-Plassmann G, Valent P, et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol 2001; 113: 357–364
   PubMed Web of Science ®Google Scholar
• Bernd H W, Sotlar K, Lorenzen J, Osieka R, Fabry U, Valent P, et al. Acute myeloid leukaemia with t(8;21) associated with “occult” mastocytosis. Report of an unusual case and review of the literature. J Clin Pathol 2004; 57: 324–328
   PubMed Web of Science ®Google Scholar
• Valent P, Akin C, Sperr W R, Horny H P, Arock M, Lechner K, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003; 122: 695–717
   PubMed Web of Science ®Google Scholar
• Horny H P, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology 2007; 74: 121–132
   PubMed Web of Science ®Google Scholar
• Mukhina G L, Buckley J T, Barber J P, Jones R J, Brodsky R A. Multilineage glycosylphosphatidylinositol anchor-deficient haematopoiesis in untreated aplastic anaemia. Br J Haematol 2001; 115: 476–482
   PubMed Web of Science ®Google Scholar
• Steensma D P, Gibbons R J, Higgs D R. Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. Blood 2005; 105: 443–452
   PubMed Web of Science ®Google Scholar
• Steensma D P, Higgs D R, Fisher C A, Gibbons R J. Acquired somatic ATRX mutations in myelodysplastic syndrome associated with alpha thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutations. Blood 2004; 103: 2019–2026
   PubMed Web of Science ®Google Scholar
• Gattermann N. From sideroblastic anemia to the role of mitochondrial DNA mutations in myelodysplastic syndromes. Leuk Res 2000; 24: 141–151
   PubMed Web of Science ®Google Scholar
• Wulfert M, Küpper A C, Tapprich C, Bottomley S S, Bowen D, Germing U, et al. Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes. Exp Hematol 2008; 36: 577–586
   PubMed Web of Science ®Google Scholar
• Shin M G, Kajigaya S, Levin B C, Young N S. Mitochondrial DNA mutations in patients with myelodysplastic syndromes. Blood 2003; 101: 3118–3125
   PubMed Web of Science ®Google Scholar
• Owen C, Barnett M, Fitzgibbon J. Familial myelodysplasia and acute myeloid leukaemia – a review. Br J Haematol 2008; 140: 123–132
   PubMed Web of Science ®Google Scholar
• Várkonyi J, Tarkovács G, Karádi I, Andrikovics H, Varga F, Varga F, et al. High incidence of hemochromatosis gene mutations in the myelodysplastic syndrome: the Budapest Study on 50 patients. Acta Haematol 2003; 109: 64–67
   PubMed Web of Science ®Google Scholar
• Nearman Z P, Szpurka H, Serio B, Warshawksy I, Theil K, Lichtin A, et al. Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts. Am J Hematol 2007; 82: 1076–1079
   PubMed Web of Science ®Google Scholar
• Várkonyi J, Demeter J, Tordai A, Andrikovics H. The significance of the hemochromatosis genetic variants in multiple myeloma in comparison to that of myelodysplastic syndrome. Ann Hematol 2006; 85: 869–871
   PubMed Web of Science ®Google Scholar
• Greenberg P L. Myelodysplastic syndromes: iron overload consequences and current chelating therapies. J Natl Compr Canc Netw 2006; 4: 91–96
   PubMedGoogle Scholar
• Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res 2007; 31: S2–S6
   PubMed Web of Science ®Google Scholar
• Valent P, Krieger O, Stauder R, Wimazal F, Nösslinger T, Sperr W R, et al. Iron overload in myelodysplastic syndromes (MDS) – diagnosis, management, and response criteria: a proposal of the Austrian MDS platform. Eur J Clin Invest 2008; 38: 143–149
   PubMed Web of Science ®Google Scholar
• Hofmann W K, de Vos S, Komor M, Hoelzer D, Wachsman W, Koeffler H P. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 2002; 100: 3553–3560
   PubMed Web of Science ®Google Scholar
• Pellagatti A, Esoof N, Watkins F, Langford C F, Vetrie D, Campbell L J, et al. Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology. Br J Haematol 2004; 125: 576–583
   PubMed Web of Science ®Google Scholar
• Pellagatti A, Fidler C, Wainscoat J S, Boultwood J. Gene expression profiling in the myelodysplastic syndromes. Hematology 2005; 10: 281–287
   PubMed Web of Science ®Google Scholar
• Paulsson K, Heidenblad M, Strömbeck B, Staaf J, Jönsson G, Borg A, et al. High-resolution genome-wide array-based comparative genome hybridization reveals cryptic chromosome changes in AML and MDS cases with trisomy 8 as the sole cytogenetic aberration. Leukemia 2006; 20: 840–846
   PubMed Web of Science ®Google Scholar
• Evers C, Beier M, Poelitz A, Hildebrandt B, Servan K, Drechsler M, et al. Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH. Genes Chromosomes Cancer 2007; 46: 1119–1128
   PubMed Web of Science ®Google Scholar
• Mohamedali A, Gäken J, Twine N A, Ingram W, Westwood N, Lea N C, et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 2007; 110: 3365–3373
   PubMed Web of Science ®Google Scholar
• Aivado M, Spentzos D, Germing U, Alterovitz G, Meng X Y, Grall F, et al. Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. Proc Natl Acad Sci USA 2007; 104: 1307–1312
   PubMed Web of Science ®Google Scholar
• Starczynowski D T, Vercauteren S, Telenius A, Sung S, Tohyama K, Brooks-Wilson A, et al. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood 2008; 112: 3412–3424
   PubMed Web of Science ®Google Scholar
• Takada S, Yamashita Y, Berezikov E, Hatanaka H, Fujiwara S I, Kurashina K, et al. MicroRNA expression profiles of human leukemias. Leukemia 2008; 22: 1274–1278
   PubMed Web of Science ®Google Scholar